Engchanil, ChulapanKosalaraksa, PopeLumbiganon, PagakrongLulitanond, ViraphongPongjunyakul, PiyapornThuennadee, RuengsinTungsawad, SasithornSuwan-apichon, Olan2009-05-272009-05-272006-08-20Engchanil C, Kosalaraksa P, Lumbiganon P, Lulitanond V, Pongjunyakul P, Thuennadee R, Tungsawad S, Suwan-apichon O. Therapeutic potential of chloroquine added to zidovudine plus didanosine for HIV-1 infected children. Journal of the Medical Association of Thailand. 2006 Aug; 89(8): 1229-36http://imsear.searo.who.int/handle/123456789/39548Chotmaihet Thangphaet.OBJECTIVE: To evaluate the efficacy and safety of CHQ in a combination treatment with ZDV/ddI in HIV-1-infected children. MATERIAL AND METHOD: Fifty five HIV-infected children were randomly enrolled into 3 treatment groups: (I) ZDV + ddI (n = 25); and (II) ZDV + ddI + CHQ (n = 21); and (III) ZDV + ddI experienced children were non-randomly added CHQ (n = 9). Weight, CD4+ T-lymphocytes and plasma HIV-RNA were measured at weeks 0, 8 and 24. RESULTS: Fifteen, 16 and 8 children from Groups I, II and III were evaluated. No significant improvement in the mean Z-score for weight in groups I and II, but a decrease occurred in group III after 6 months of therapy. In group I, II and III, the respective change in the mean CD4+ T-lymphocyte percentage was +6.7, +4.0 and -0.6. The decrease in the plasma HIV-RNA log was 0.9, 1.1 and 0.7, respectively. There was a trend for more nausea/vomiting in group II/III and more opportunistic infections in group III. CONCLUSION: 1. The addition of chloroquine in ZDV/ddI regimen provided no significant improvement in clinical, immunological and virological parameters. 2. Chloroquine induced immunosuppression and nausea complicated its use.engAnti-HIV Agents --therapeutic useAntimalarials --therapeutic useChildChild, PreschoolChloroquine --therapeutic useDidanosine --therapeutic useFemaleHIV Infections --drug therapyHIV-1 --drug effectsHumansMaleZidovudine --therapeutic useJournal Article